OmniScience and INmune Bio Partner to Accelerate Phase 2 Alzheimer's Trial with Vivo AI Control Tower

OmniScience and INmune Bio have formed a strategic partnership to innovate the management of INmune Bio’s global Phase 2 Alzheimer’s disease clinical trial, known as the AD02 trial, through the use of OmniScience’s advanced product, Vivo. This collaboration aims to revolutionize clinical data analysis by integrating data from various sources in real time, thereby enhancing decision-making processes.

Vivo, powered by generative AI, serves as a centralized control tower that collects and analyzes data from multiple systems, including electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, laboratories, sensors, and safety databases. The platform’s ability to unify data allows clinical teams to make faster and more informed decisions, improving patient safety and overall health outcomes. Vivo’s design emphasizes explainability and interpretability, ensuring that every insight provided is backed by clear and traceable data.

The AD02 trial, which recently finished patient randomization, enrolled a total of 208 participants, outstripping initial expectations. Among these participants, 56% were identified with mild Alzheimer’s disease and 44% with mild cognitive impairment. INmune Bio plans to disclose preliminary cognitive results in the second quarter of 2025. Tara Lehner, INmune Bio’s VP of Clinical Operations, highlighted the importance of Vivo in analyzing cognitive results efficiently. She emphasized that Vivo’s generative AI capabilities enable the clinical teams to transform complex data into actionable insights rapidly, thus expediting the process of bringing treatments to patients.

The partnership has already shown promising results during the initial rollout of Vivo to INmune Bio’s clinical development team. Some of the significant improvements observed include:

1. Enhanced data quality through automatic detection of discrepancies.
2. Improved visualization of clinical outcome assessments, aiding in the identification of outliers and better comprehension of population distributions.
3. Real-time responses that aid decision-making regarding patient enrollment while they are still in the clinic.
4. Reduced dependence on traditional, time-intensive spreadsheet-based data analysis, fostering better collaboration between clinical and executive teams.

Angela Holmes, CEO of OmniScience, expressed their shared vision with INmune Bio to transform clinical trial data into real-time knowledge. This transformation aims to enhance decision-making and increase the likelihood of trial success. Holmes also noted that the continuous feedback from INmune Bio is instrumental in further developing Vivo’s capabilities.

Michael Bell, VP of Product at OmniScience, underscored that the future demands smarter solutions for clinical trials, with Vivo embodying this evolution. The collaboration with INmune Bio provides valuable insights that help OmniScience’s development team refine Vivo. This hands-on approach builds user confidence by demonstrating how generative AI can swiftly convert data into actionable insights and improve daily workflows.

OmniScience is dedicated to advancing clinical research and development through its expertise in clinical data science. Vivo, their flagship product, represents a groundbreaking platform that eliminates the need for traditional data management tools like spreadsheets and SQL queries. Vivo's real-time insights greatly enhance the efficiency and effectiveness of clinical trial operations.

INmune Bio, a publicly traded biotechnology company, focuses on developing treatments targeting the innate immune system to combat various diseases. They have two main product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform and the Natural Killer Cell Priming Platform. These platforms aim to treat conditions such as cancer, mild Alzheimer’s disease, mild cognitive impairment, and treatment-resistant depression.

In summary, the collaboration between OmniScience and INmune Bio, leveraging the innovative Vivo platform, marks a significant advancement in the management of clinical trials. By integrating real-time data analysis and generative AI, this partnership aims to improve clinical trial outcomes and accelerate the development of new treatments.